Merck Opens Defense In Australian Class-Action Vioxx Suit
This article was originally published in PharmAsia News
U.S. drug maker Merck said in an Australian trial there is no scientific link between its Vioxx (rofecoxib) and heart attacks reported in patients taking the drug to treat arthritis. A Merck attorney made the statement in a court trying a case involving the death of one of 1,000 Australians suing the company in a class-action suit. The counsel said evidence of a nexus between the drug and increased heart risk "remains contradictory and uncertain." The lawyer presented the stance in his opening argument as the defense began its side of the case. (Click here for more
You may also be interested in...
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.